Andreas Schüller
- Position
- Associate Professor
- Academic unit
- Biomedicine Area, School of Biological Sciences
- Lines of Research
- Chemoinformatics
- Bioinformatics
- Computer-aided drug design
- Scientific software engineering
- Summary
Associate Professor at Pontificia Universidad Católica de Chile with more than 15 years of independent and postdoctoral experience in research, teaching and mentoring at universities in Germany, Singapore, New York and Chile.
His laboratory is dedicated to deciphering the molecular code of protein-ligand interactions at the atomic level. His work is in the areas of bioinformatics and chemoinformatics, where he develops new computational methods for the prediction of molecular binding events using concepts from structural biology, biochemistry, drug design, big data, machine learning, protein engineering and software engineering.
These computational methods are then applied in his research for drug repositioning, the discovery of antitumor, antiviral, antifungal and anticoagulant compounds, as well as the design of gut microbiota modulating oligopeptides.
For more information on Dr. Schüller's research, visit his website here (http://www.schuellerlab.org/).
- Biochemist, University of Frankfurt, Germany, 2004.
- D. in Natural Sciences (Dr. Phil. Nat.) with mention in Chemistry, University of Frankfurt, Germany, 2009.
- One Health Interdisciplinary Seed Fund, UC (2024 - 2025). "Identification of antiviral compounds to inhibit the Hantavirus Andes entry process". Alternate Director. Amount of funding:
- Fondecyt Regular (2018 - 2021). "Synthesis of coagulation inhibitors coupled to nanoparticles with activity against factor Xa and platelet aggregation. A green chemistry strategy for the development of dual antithrombotic agents". Co-investigator. Amount of funding:
- Fondecyt Regular (2016 - 2019). "Development of a hybrid ligand- and structure-based method for small molecule target prediction". Principal Investigator. Funding amount:
- Fondecyt Regular (2013 - 2016). "Assessment of rationally designed small molecule inhibitors targeting the human respiratory syncytial virus matrix protein". Principal Investigator. Amount of funding: